3324 NCCTG N0879 (Alliance): A randomized phase II cooperative group trial of carboplatin, paclitaxel, bevacizumab, =/- everolimus (CPB+/-E) for metastatic melanoma von McWilliams, R.R, Allred, J, Kottschade, L, Erickson, L, Katipamula, R, Gupta, M, Dronca, R, Rumilla, K, Markovic, S

Volltext

Safety and Efficacy Results of a Phase II Clinical Trial Evaluating Moderately-Hypofractionated Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma von Merrell, K.W., Hallemeier, C.L., Harmsen, W.S., Ashman, J.B., Truty, M., Leenstra, J.L., Timm, M.A., Owen, D., Thiels, C., Stucky, C.C.H., Wittich, M. Neben, Bekaii-Saab, T., Rule, W.G., Garces, Y., McWilliams, R.R., Lester, S.C., Haddock, M.G., Sio, T.T.W., Jethwa, K.R.

Volltext

Adjuvant Radiation and Chemotherapy for Pancreatic Adenocarcinoma: The Mayo Clinic Experience von Corsini, M.M, Miller, R.C, Haddock, M.G, Donohue, J.H, Farnell, M.B, Nagorney, D.M, Jatoi, A, McWilliams, R.R, Bhatia, S, Gunderson, L.L

Volltext

730P - Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC) von Chakrabarti, S., Zemla, T., Ou, F.-S., Fruth, B., Ahn, D., Borad, M.J., Hartgers, M.L., Wessling, J., Walkes, R.L., Alberts, S., McWilliams, R.R., Liu, M.C., Mahipal, A.

Volltext

Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC) von Chakrabarti, S., Zemla, T., Ou, F.-S., Fruth, B., Ahn, D., Borad, M.J., Hartgers, M.L., Wessling, J., Walkes, R.L., Alberts, S., McWilliams, R.R., Liu, M.C., Mahipal, A.

Volltext

Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 von Marabelle, A., Fakih, M.G., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H.C., Kindler, H.L., Lopez-Martin, J.A., Miller, W., Italiano, A., Kao, S., Piha-Paul, S.A., Delord, J.-P., McWilliams, R.R., Aurora-Garg, D., Chen, M., Jin, F., Norwood, K., Bang, Y.-J.

Volltext

1192O - Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 von Marabelle, A., Fakih, M.G., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H.C., Kindler, H.L., Lopez-Martin, J.A., Miller, W., Italiano, A., Kao, S., Piha-Paul, S.A., Delord, J.-P., McWilliams, R.R., Aurora-Garg, D., Chen, M., Jin, F., Norwood, K., Bang, Y.-J.

Volltext